Initial experience with golimumab in clinical practice for ulcerative colitis

Revista Española De Enfermedades Digestivas : Organo Oficial De La Sociedad Española De Patología Digestiva
Luisa Castro-LariaJuan Manuel Herrerías-Gutiérrez

Abstract

Golimumab is a TNF-blocking agent indicated as a second-line therapy in ulcerative colitis. To research the effectiveness and safety of golimumab in patients with ulcerative colitis in clinical practice. Retrospective study of the effectiveness and safety of golimumab in patients with ulcerative colitis. All patients received golimumab 200 mg subcutaneously at week 0, and golimumab 100 mg subcutaneously at week 2. After the induction treatment, each patient received 50 mg sc. every 4 weeks in patients with body weight less than 80 kg, and 100 mg every 4 weeks in patients with body weight greater than or equal to 80 kg. Study of a group of 23 ulcerative colitis patients, 7 of whom were naive to any anti-TNF therapy, and 16 patients who had previously been treated with an anti-TNF agent other than golimumab (non-naive patients). The average treatment time with golimumab was 14.3 weeks. Globally, withdrawal of corticosteroids was observed in 74% of cases. Clinical response was observed in 85.5% of patients who had not received biological treatment previously, and in patients who had previously received biological treatment the response rate was 75%. In this short study, golimumab seems to be an alternative treatment in naive and n...Continue Reading

References

Dec 24, 1987·The New England Journal of Medicine·K W SchroederD M Ilstrup
Nov 6, 2008·Inflammatory Bowel Diseases·Siew C Ng, Michael A Kamm
Nov 15, 2011·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Esther Garcia-PlanellaEugeni Domènech
Jun 6, 2013·Gastroenterology·William J SandbornUNKNOWN PURSUIT-SC Study Group
Jun 19, 2013·Gastroenterology·William J SandbornUNKNOWN PURSUIT-Maintenance Study Group
Jun 25, 2013·Autoimmunity Reviews·Shomron Ben-HorinYehuda Chowers
Nov 20, 2013·Digestive Diseases·Ivanka CurkovicGerd A Kullak-Ublick
Apr 4, 2014·World Journal of Gastroenterology : WJG·Talia Zenlea, Mark A Peppercorn
Jul 22, 2014·Journal of Gastroenterology and Hepatology·David KevansMark Silverberg
Aug 19, 2014·World Journal of Gastrointestinal Pathophysiology·Evanthia ZampeliGiorgos Bamias
Jan 23, 2015·Therapeutics and Clinical Risk Management·Rebecca Fausel, Anita Afzali

❮ Previous
Next ❯

Citations

Jul 27, 2018·Frontline Gastroenterology·Mark A SamaanPeter M Irving
Jan 7, 2017·World Journal of Gastroenterology : WJG·Marta Maia Bosca-WattsJose Maria Paredes

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.